AVEO Pharmaceuticals, Inc.
| Nasdaq: AVEO
AVEO Pharmaceuticals, Inc. is a cancer therapeutics company, which is discovering, developing and commercializing targeted therapies to treat patients with cancer. Its proprietary human response platform provides the company unique insights into cancer and related disease biology and is being leveraged in the discovery and clinical development of its therapeutic candidates. The company's product candidates include AV-203, ficlatuzumab, tivozanib and AV-380. AVEO Pharmaceuticals was founded by Ronald A. DePinho, Lynda Chin and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.